Research shows that up to 45 percent of breast tumors exhibit genetic alterations affecting the CYP2D6 gene. Use of tumor tissue to obtain DNA distorts the patient's true or inherited CYP2D6 genotype.

Recently approved by the FDA and simultaneously covered by Medicare, Cologuard is a noninvasive stool DNA screening test for colorectal cancer with demonstrated 92 percent sensitivity in detecting cancer stages I-IV and 94 percent sensitivity for detecting early-stage CRC.

About 15 percent of patients with colorectal liver metastases are candidates for potentially curative surgical resection, but many don't receive it. Experienced centers with multidisciplinary teams can now successfully treat some patients whose tumors were once considered unresectable.

Trials enroll patients to study immunotherapies for glioblastomas
Analysis of clinical-grade brain-tumor cell lines from patients with newly diagnosed glioblastomas pinpointed antigens commonly present in brain tumors, allowing development of tests for specific antigen responses and eliminating reliance on tumor samples to create vaccine for each patient.

A new approach to discovering medical biomarkers at Mayo Clinic has led to 32 molecular cancer discoveries in 2013 alone and to dozens of tests that physicians can use to aid patients.

Hematologic Malignancies: New Therapies and the Evolving Role of Transplant 2015
April 10-11, 2015, in Chicago
Mayo faculty discuss strategies to determine appropriate therapies for patients with hematologic malignancies, integration of the blood and marrow transplantation process into current treatment strategies when indicated to improve outcomes, and innovations and limitations in stem cell mobilization.

Mayo Clinic Oncology Review 2015
July 25, 2015
Review the most recent advances in the treatment of various oncologic malignancies, based on abstracts presented at the June 2015 annual meeting of the American Society of Clinical Oncology.

25th Annual Mayo Clinic Hematology/Oncology Reviews 2015
July 29-Aug. 1, 2015, in Amelia Island, Fla.
This comprehensive review of hematology and oncology topics emphasizes recent developments and updates on the evaluation and treatment of cancer and blood disorders.

See all Hematology & Oncology Continuous Professional Development courses

Targeting Polarity Pathways for Cancer Treatment
In this Grand Rounds presentation, Panagiotis Z. Anastasiadis, Ph.D., discusses the role of polarity complexes in normal cell morphology and behavior, the role of polarity dysfunction in promoting tumor growth and dissemination, and the difficulties and potential of targeting polarity pathways in cancer.

View videos by specialty and Grand Rounds presentations online

• Phoenix/Scottsdale, Arizona
  866-629-6362 (toll-free)
• Jacksonville, Florida
  800-634-1417 (toll-free)
• Rochester, Minnesota
  800-533-1564 (toll-free)
• Online Referrals

• Career Opportunities
• Clinical Trials at Mayo Clinic
• Mayo School of Continuous Professional Development